Live feed16:00:00·1411dPRReleasevia QuantisnowPTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular DystrophyByQuantisnow·Wall Street's wire, on your screen.PTCT· PTC Therapeutics Inc.Health Care